Publication
Article
Facing Type 2 Diabetes in the Healthcare Reform Era
This supplement to The American Journal of Managed Care explores the current status of diabetes management, clinical challenges and barriers faced by patients, physicians, and the healthcare system, and potential strategies and initiatives to improve diabetes care. The content is based on presentations and discussion at a roundtable meeting held October 15-16, 2010, in Chicago, Illinois.
The contents of this supplement may include information regarding the use of products that may be inconsistent with or outside the approved labeling for these products in the United States. Physicians should note that the use of these products outside current approved labeling is considered experimental and are advised to consult prescribing information for these products.
Faculty
Moderator and Presenter
A. Mark Fendrick, MD
University of Michigan Center for Value-
Based Insurance Design
Ann Arbor, Michigan
Presenters
Michael A. Bush, MD
Past Clinical Chief, Division of Endocrinology, Cedars-Sinai Medical Center
Clinical Associate Professor of Medicine
David Geffen School of Medicine, UCLA
Los Angeles, California
Bruce Niebylski, MD
Associate Vice President
Priority Health
Bloomfield Hills, Michigan
Participants
Louis L. Brunetti, MD, JD
Senior Vice President and Chief Medical Officer
MedImpact Healthcare Systems, Inc
San Diego, California
R. Keith Campbell, RPh, MBA
Distinguished Professor in Diabetes Care/Pharmacotherapy
Washington State University College of Pharmacy
Pullman, Washington
Andrea Dunaif, MD
Division of Endocrinology, Metabolism, and Molecular Medicine
Northwestern University
Feinberg School of Medicine
Chicago, Illinois
Hugh Fatodu, RPh, MBA
Director of Pharmacy
Johns Hopkins HealthCare
Glen Burnie, Maryland
Michael Miller, MD, FACC, FAHA
Professor of Medicine, Epidemiology &
Public Health
University of Maryland School of Medicine
Director, Center for Preventive Cardiology
University of Maryland Hospital
Baltimore, Maryland
James L. Rosenzweig, MD
Director of Diabetes Services
Boston Medical Center
Associate Professor of Medicine
Boston University School of Medicine
Boston, Massachusetts
Curtis Triplitt, PharmD, CDE
Assistant Professor
Department of Medicine
Division of Diabetes
UTHSCSA Texas Diabetes Institute
San Antonio, Texas
Medical Writer
William James Yarnall, RPh, CCP
DoctorLearns, LLC
Merchantville, New Jersey
Faculty Disclosures
These faculty disclosed the following relevant commercial financial relationships or affiliations in the past 12 months:
Louis L. Brunetti, MD, JD
Honoraria: Amylin; Pfizer; sanofi-aventis; Takeda
Michael A. Bush, MD
Speakers' Bureau: AstraZeneca; Bristol- Myers Squibb; Lilly; Merck; Novo Nordisk
Meeting/Conference Attendance: Novo Nordisk; Merck
R. Keith Campbell, RPh, MBA
Honoraria: Lilly
A. Mark Fendrick, MD
Consultant: Abbott Laboratories; ActiveHealth Management, Inc; AstraZeneca; Avalere Health LLC; Blue Cross and Blue Shield Association; GlaxoSmithKline; Hewitt Associates LLC; MedImpact HeathCare Systems, Inc; Perrigo; Pfizer; The Regence Group; sanofi-aventis U.S. LLC; WebMD, LLC; UCB, Inc.
Lectureship: Merck; Pfizer; sanofi-aventis U.S. LLC.
Grants: Abbott Laboratories; AstraZeneca; Lilly; GlaxoSmithKline; Merck; Novartis Corporation; Pfizer; sanofi-aventis U.S. LLC.
James L. Rosenzweig, MD
Scientific Advisory Board: Alere, LLC
Curtis Triplitt, PharmD, CDE
Consultant: Roche; Takeda
Honoraria: Amylin; Lilly; Roche
Andrea Dunaif, MD; Hugh Fatodu, RPh, MBA; Michael Miller, MD, FACC, FAHA; Bruce Niebylski, MD; and WilliamJames Yarnall, RPh, CCP.
The following faculty members have nothing to disclose relevant to the content of this supplement:
The planning staff from the University of Cincinnati, The American Journal of Managed Care, and the Pharmacy Times Office of Continuing Professional Education have no relevant financial relationships to disclose.
Facing Type 2 Diabetes in the Healthcare Reform Era
Release date: December 20, 2010
Expiration date: December 20, 2011
Estimated time to complete activity: 2.5 hours
This activity is supported by an educational grant from Amylin Pharmaceuticals, Inc and Lilly USA, LLC.
Intended Audience
The audience for this supplement is medical directors, pharmacy directors, pharmacy and therapeutic committee members, and healthcare providers who see patients with type 2 diabetes mellitus (T2DM) in various clinical settings.
Statement of Educational Need/Program Overview
T2DM is widespread and increasing in prevalence. In 2007, 23.6 million Americans, or 7.8% of the US population, had diabetes; 57 million more had prediabetes. Patients with T2DM often have comorbidities, and they are at double the risk of death compared with those without diabetes. Because of its chronic nature and prevalence, diabetes comes at an exorbitant cost.
The increasing prevalence of T2DM is directly related to the steadily rising rate of obesity in the United States. Life expectancy in the United States has increased over the last 200 years; however, the impact of the obesity epidemic and its relation to diabetes is threatening to reverse that trend in the 21st century.
There are many pharmacologic agents currently on the market to combat T2DM and its various comorbidities, but efforts to reduce rampant cardiovascular disease risk in patients with diabetes have proved insufficient. An intensified, multifactorial approach has shown to be effective, but incorporating multiple therapies and differing dosing regimens often leads to nonadherence and therapeutic failure. Several new healthcare practices could potentially provide a solution for the growing diabetes problem. Although not implemented or widely known, value-based insurance design, the Asheville Project, and comparative effectiveness research are just a few of the models that could provide patients with diabetes a successful alternative to battling their disease.
Educational Objectives
After completing this activity, the participant should be able to:
Disclosure Policy
According to the disclosure policies of the University of Cincinnati and Pharmacy Times Office of Continuing Professional Education, faculty, editors, managers, and other individuals who are in a position to control content are required to disclose any relevant financial relationships with relevant commercial companies related to this activity. All relevant conflicts of interest that are identified are reviewed for potential conflicts of interest. If a conflict is identified, it is the responsibility of the University of Cincinnati and Pharmacy Times Office of Continuing Professional Education to initiate a mechanism to resolve the conflict(s). The existence of these interests or relationships is not viewed as implying bias or decreasing the value of the presentation.
All educational materials are reviewed for fair balance, scientific objectivity of studies reported, and levels of evidence.
Physician Continuing Medical Education
Accreditation Statement
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the University of Cincinnati. The University of Cincinnati is accredited by the ACCME to provide continuing medical education for physicians.
Credit Designation
The University of Cincinnati designates this educational activity for a maximum of 2.5 AMA PRA Category 1 Credit(s)TM. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Pharmacist Continuing Education
Accreditation Statement Pharmacy Times Office of Continuing Professional Education is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This program is approved for 2.5 contact hours (0.25 CEUs) under the ACPE universal program number of 0290-9999-10-027-H01-P. This program is available for CE credit through December 20, 2011.